417 related articles for article (PubMed ID: 30797468)
1. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
Koessler T; Addeo A; Nouspikel T
Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
[TBL] [Abstract][Full Text] [Related]
2. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
3. The Introduction and Clinical Application of Cell-Free Tumor DNA.
Li J; Liu R; Huang C; Chen S; Xu M
Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Valpione S; Campana L
Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
[TBL] [Abstract][Full Text] [Related]
6. The cornerstone of integrating circulating tumor DNA into cancer management.
Li Z; Yi L; Gao P; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):1-11. PubMed ID: 30419316
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy: unlocking the potentials of cell-free DNA.
Chu D; Park BH
Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
[TBL] [Abstract][Full Text] [Related]
8. Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies.
Marass F; Castro-Giner F; Szczerba BM; Jahn K; Kuipers J; Aceto N; Beerenwinkel N
Recent Results Cancer Res; 2020; 215():347-368. PubMed ID: 31605238
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
10. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
Rossi G; Ignatiadis M
Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory.
Nikolaev S; Lemmens L; Koessler T; Blouin JL; Nouspikel T
Anal Biochem; 2018 Feb; 542():34-39. PubMed ID: 29137972
[TBL] [Abstract][Full Text] [Related]
12. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
14. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
15. How liquid biopsies can change clinical practice in oncology.
Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
[TBL] [Abstract][Full Text] [Related]
16. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.
Hahn AW; Stenehjem D; Nussenzveig R; Carroll E; Bailey E; Batten J; Maughan BL; Agarwal N
Cancer Treat Res Commun; 2019; 19():100120. PubMed ID: 30743187
[TBL] [Abstract][Full Text] [Related]
19. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
20. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
